Diagnostic methods and criteria are not certified in this packet. One listed clinical trial, NCT02063399, is titled as a prospective nasopharyngeal carcinoma screening study using plasma Epstein-Barr virus DNA analysis; the trial title alone does not establish a diagnostic approach.

According to the packet's approved-treatment records, LOQTORZI (toripalimab-tpzi), a BLA product, received FDA approval on 2023-10-27 and has an ACTIVE market status. The packet's orphan-drug listing associates Loqtorzi with the indication of treatment of nasopharyngeal carcinoma. The packet's orphan-drug listing also includes several products with DESIGNATED status for nasopharyngeal carcinoma, including pembrolizumab, tislelizumab, and nanatinostat with valganciclovir; orphan designation is not FDA approval. The packet certifies no foundational or supportive therapies and no stage-specific treatment information.

Prognosis and natural history are not certified in this packet.

According to ClinicalTrials.gov records summarized in the packet, numerous active studies are associated with this condition. Examples with nasopharyngeal carcinoma in the title include NCT06029270, a Phase 2 study sponsored by the National Cancer Institute that adds relatlimab to immunotherapy in recurrent or metastatic nasopharyngeal cancer (recruiting; 2024-07-15 to 2029-04-30); NCT04875611, a Phase 2 nivolumab study sponsored by the Maria Sklodowska-Curie National Research Institute of Oncology (recruiting; 2021-08-26 to 2027-12-31); and NCT06064097, a Phase 2 study of nivolumab with chemotherapy drugs sponsored by the National Cancer Institute (recruiting; 2024-06-25 to 2027-03-31). A search link for ClinicalTrials.gov is included in the packet. Trial titles do not establish the effect of any intervention.